CLINICAL TRIALS PROFILE FOR BESIVANCE
✉ Email this page to a colleague
All Clinical Trials for besivance
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00347932 ↗ | A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis. | Completed | Bausch & Lomb Incorporated | Phase 3 | 2006-06-01 | Evaluation of the clinical and microbial efficacy of 0.6% ISV-403, compared to vehicle in the treatment of bacterial conjunctivitis. |
| NCT00824070 ↗ | Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects | Completed | Bausch & Lomb Incorporated | Phase 1 | 2009-02-01 | This study is being conducted to assess the concentration of besifloxacin, moxifloxacin, or gatifloxacin in aqueous humor samples collected following topical instillation of the associated formulation in subjects undergoing cataract surgery. |
| NCT00905762 ↗ | Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation | Completed | Bausch & Lomb Incorporated | Phase 1 | 2009-03-01 | The purpose of this study is to assess the concentration of besifloxacin compared to gatifloxacin and moxifloxacin in human conjunctival tissue, following a single drop of the drug instilled topically into the study eye. Conjunctival biopsies will be performed at specified time points, followed by the use of loteprednol etabonate/tobramycin ophthalmic suspension four times a day for 5 days. |
| NCT00924729 ↗ | Study of Ocular Penetration of Topically Administered Fluoroquinolones | Completed | Johns Hopkins University | Phase 4 | 2009-09-01 | This study is being conducted to evaluate the intraocular penetration of Moxifloxacin 0.5% ophthalmic solution (Vigamox) and Besifloxacin 0.6% ophthalmic suspension (Besivance) after pre-operative topical administration in subjects undergoing cataract surgery. |
| NCT00972777 ↗ | Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis | Completed | Bausch & Lomb Incorporated | Phase 2/Phase 3 | 2009-10-01 | This study is being conducted to evaluate the clinical and microbial efficacy of besifloxacin ophthalmic suspension compared with vehicle in the treatment of bacterial conjunctivitis. This study was conducted as a phase IIb study and continued with further enrollment as a phase III study. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for besivance
Condition Name
Clinical Trial Locations for besivance
Trials by Country
Clinical Trial Progress for besivance
Clinical Trial Phase
Clinical Trial Sponsors for besivance
Sponsor Name
